Plus therapeutics to present data from ongoing respect™ clinical trials at the annual conference on cns clinical trials and brain metastases

Austin, texas, july 28, 2022 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from two ongoing clinical trials for recurrent glioblastoma and leptomeningeal metastases at the 2022 annual conference on cns clinical trials and brain metastases, co-sponsored by the society for neuro-oncology (sno) and the american society of clinical oncology (asco), being held august 12-13, 2022 in toronto, canada.
pstv Ratings Summary
pstv Quant Ranking